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Abstract
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Colorectal cancer (CRC) is the third most common solid internal malignancy among cancers.
Early detection of cancer is key to increasing the survival rate of colorectal cancer patients.
Overexpression of the EGFR protein is associated with CRC. We have designed a series of
peptides that are highly specific for the extracellular domain of EGFR, based on our earlier studies
on linear peptides. The previously reported linear peptide LARLLT, known to bind to EGFR, was
modified with the goals of increasing its stability and its specificity towards EGFR. Peptide
modifications, including D-amino acid substitution, cyclization, and chain reversal, were
investigated. In addition, to facilitate labeling of the peptide with a fluorescent dye, an additional
lysine residue was introduced onto the linear (KLARLLT) and cyclic peptides cyclo(KLARLLT)
(Cyclo.L1). The lysine residue was also converted into an azide group in both a linear and
reversed cyclic peptide sequences cyclo(K(N3)larllt)(Cyclo.L1.1) to allow for subsequent “click”
conjugation. The cyclic peptides showed enhanced binding to EGFR by SPR. NMR and molecular
modeling studies suggest that the peptides acquire a β-turn structure in solution. In vitro stability
studies in human serum show that the cyclic peptide is more stable than the linear peptide.
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Based on the linear peptides that have an affinity for EGFR extracellular domain, cyclic peptides
with enhanced affinity and stability were designed. Cyclic peptides exhibited serum stability and
binding to EGFR protein. Such peptides can be conjugated with fluorescent labels for imaging
EGFR overexpressed colon cancer.
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Epidermal growth factor receptor (EGFR) has been implicated in tumor-specific targeted
therapy and diagnosis. EGFR overexpression is frequently found in breast, lung, colon and
ovarian cancers (1). Among the different types of cancers, colorectal cancer (CRC) is the
third most common solid internal malignancy. Over 50,000 deaths in the U.S. are attributed
to this disease, making it second only to lung cancer in U.S. cancer mortality (2). Although
recent studies suggest that the overall CRC incidence in the U.S. is decreasing, driven by
screening, the incidence in young adults under the age of 50 years in still increasing (3).
Disease progression of colon cancer is typically slow and happens in a linear fashion from
adenomatous polyps to carcinoma. Early stage detection by screening and removal of polyp
adenomas can reduce the incidence of CRC by about 80% (2). Indeed, the advent of broader
population screening has largely led to the improvement in mortality observed during the
past 20 years (2). Since EGFR has a strong association with several cancers including CRC,
with approximately 97% detected in all of the colon cancers, it is a convenient target for
ligands, such as peptides and antibodies, for targeted drug or gene delivery. EGFR is overexpressed even on small cancers (< 5 mm) and on the flat, dysplastic, aberrant crypt foci that
are believed to precede cancer development (4). These are the types of lesions most often
missed by standard colonoscopy (5).
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We have recently prepared and investigated EGFR-targeted porphyrin-peptide and
phthalocyanine-peptide conjugates (6, 7). Two small peptides with sequences LARLLT (L1)
and YHWYGYTPQNVI (L2) were used in these studies, due to their reported ability for
EGFR targeting, both in vitro and in vivo (8, 9). The conjugates with L1 linked via a low
molecular weight PEG spacer showed enhanced water solubility compared with the
conjugates to the longer hydrophobic peptide. Furthermore, the LARLLT-bearing conjugates
showed higher EGFR targeting ability, accumulating in EGFR over-expressing cells up to
17-fold compared with unconjugated fluorophore. These results suggest that fluorophoreLARLLT conjugates have substantially increased EGFR-targeting ability, and could be very
useful for the early detection and diagnosis of CRC. Our previous studies also showed that
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the peptide L1 conjugates bind to EGFR with higher affinity compared with the L2-based
conjugates (7). However, L1 is a linear peptide with limited in vivo stability (10, 11).
Several strategies exist to improve the stability of peptides in vivo, including cyclization, Nand C-termini modification, and D-amino acid substitution (12, 13). In the present work, we
investigated several strategies for modification of the L1 peptide. In addition to enhanced in
vivo stability, we also introduced functionalization for easy conjugation to fluorophores, via
the addition of a lysine residue or an azide-transformed lysine that can be used in “click”
conjugations (14, 15). We investigated the EGFR-binding ability of the resulting peptides by
surface plasmon resonance (SPR) and molecular docking studies. Our results reveal that the
cyclic D-amino acid version of the linear L1 peptide binds to EGFR with higher affinity, and
it is more stable in human serum than the linear peptide.

Materials and Methods
Author Manuscript

Materials
All the chemicals, reagents, solvents and cell lines were from commercial sources. Fmocprotected amino acids, 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium
hexafluorophosphate (HCTU) and trifluoroacetic acid (TFA) were purchased from
Advanced ChemTech, Louisville, KY. Chlorotrityl chloride resin (CTC) was purchased from
ChemImpex, Wood Dale, IL. Diisopropylethyl amine (DIEA), methanol (MeOH),
chloroform, acetic acid and azidoacetic acid were purchased from Sigma-Aldrich, St. Louis,
MO. Dimethylformamide (DMF), dichloromethane (DCM) and triisopropylsilane (TIPS)
were purchased from Protein Technologies, Tucson, AZ., N-[(Dimethylamino)-1H-1,2,3triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate Noxide (HATU) was purchased from ChemPep (Wellington, FL).
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General Synthesis Procedure
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All linear peptides were synthesized using solid phase peptide synthesis (SPPS) and Fmoc
chemistry. Peptides were synthesized using Fmoc-PAL-PEG-PS on a 0.2 mmol scale, and a
4-fold excess of the Fmoc protected amino acids in the presence of HOBt and TBTU as the
activating agents were used for SPPS. Final deprotection of Fmoc from the last amino acid
was achieved by washing the peptidic resin beads five times with DMF and six times with
DCM, followed by drying under vacuum for 6 hours. Peptide was cleaved from the resin
using a cocktail consisting of 94% TFA/2.5% liquid phenol/2.5% water/1% TIPS. After
washing, cold diethyl ether was added to the mixture to precipitate the peptide, and the
mixture centrifuged and lyophilized. Peptides were purified using reversed-phase HPLC
(Waters, MA USA). Analytical HPLC was carried out using a XBridge, 4.6 mm × 250 mm
(Waters, MA, USA) column with a stepwise gradient. The purity of the peptides was
determined by HPLC. A general procedure for the synthesis of peptides is provided in
Scheme 1.
Synthesis of peptides L1, and L1.1 – L1.7
Title compounds were synthesized on a Tribute peptide synthesizer (Protein Technologies,
Tucson, AZ) utilizing a standard Fmoc peptide chemistry protocol on a 125 μmol scale using
the previously loaded H-(d)Leu-CTC resin. Side-chain functionalities were protected with
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tert-butyl (Thr) and NG-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Arg). Five fold
excess of Fmoc-amino acids and HCTU, in the presence of 10 equivalents of DIEA were
used for each of the coupling steps (10 min) with DMF as the solvent. After the synthesis of
each sequence was complete, the final Fmoc groups were removed using 20% piperidine in
DMF (1 × 5 min; 1 × 10 min). The resin from each synthesis was washed with DMF (5 × 30
sec) and DCM (5 × 30 sec). In the case of L1.4, azidoacetic acid was coupled using the same
procedure as other amino acids. The peptides were simultaneously side chain deprotected
and cleaved from the resin using TFA:TIPS:water (95:2.5:2.5) for 2 hours, then filtered to
remove the resin. Cold diethyl ether was then added to the peptide solutions to precipitate
the crude peptides. The peptides were centrifuged for 10 minutes (10,000 rpm) and the ether
layers decanted. Fresh cold diethyl ether was added, and the pelleted peptides were resuspended. The peptides were centrifuged again, and the procedure was repeated 5 times for
each peptide. Each peptide pellet was dissolved in 5 mL of water containing 0.1% TFA,
frozen and lyophilized to yield the crude peptide powders. Peptides were purified as
described in section 2.2.
L1: Peptide Sequence: LARLLT-CONH2
Confirmation by MS(MALDI-TOF): m/z 685.390; calc’d. for C31H61N10O7+ 685.891. 1H
NMR (500 MHz, DMSO-d6, 308K): δ 8.65 (d, J= 7.4 Hz, 2H), 8.10 (d, J = 7.9 Hz, 4H),
7.91 (d, J = 8.1 Hz, 2H), 7.52 (t, J = 5.8 Hz, 1H), 7.44 (d, J = 8.5 Hz, 2H), 7.09 (d, J = 9.0
Hz, 3H), 4.41 (t, J = 7.2 Hz, 2H), 4.33 (t, J = 7.8 Hz, 3H), 4.27 (d, J = 7.1 Hz, 1H), 4.07 (dd,
J = 8.4 Hz, J= 3.3 Hz, 2H), 4.02 (s, 1H), 3.80 (s, 1H), 2.53-1.55 (m, 9H), 1.57-1.38 (m, 8H),
1.24 (d, J = 6.7 Hz, 5H), 1.00 (d, J = 6.3 Hz, 3H), 0.98-.52 (m, 18H).
L1.1: Peptide Sequence: larllt-COOH
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Confirmation by MS (MALDI-TOF): m/z 686.451; calc’d for C31H60N9O8+ 686.875. 1H
NMR (500 MHz, DMSO-d6) δ 8.71 (d, J = 7.5 Hz, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.97 (d, J
= 8.6 Hz, 1H), 7.55 (s, 1H), 7.25 (s, 1H), 4.51-3.94 (m, 6H), 3.85-3.77 (m, 1H), 3.09 (t, J =
6.6 Hz, 2H), 1.72 (d, J = 13.4 Hz, 1H), 1.72-1.57 (m, 4H), 1.56-1.37 (m, 9H), 1.26 (d, J =
7.1 Hz, 3H), 1.03 (d, J = 6.1 Hz, 3H), 0.97-0.74 (m, 18H).
L1.2: Peptide Sequence: tllral-COOH
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Confirmation by MS (MALDI-TOF): m/z 686.451; calc’d for C31H60N9O8+ 686.875. 1H
NMR (500 MHz, DMSO-d6) δ 8.60 (d, J = 8.3 Hz, 1H), 8.27 (d, J = 8.2 Hz, 1H), 8.09 (s,
1H), 7.93 (d, J = 7.8 Hz, 1H), 7.25 (s, 1H), 4.41 (dd, J = 9.4 Hz, J = 5.7 Hz, 1H), 4.37-3.94
(m, 4H), 3.92-3.64 (m, 1H), 3.57 (d, J = 7.6 Hz, 1H), 3.20-2.91 (m, 2H), 1.73 (s, 1H),
1.71-1.57 (m, 4H), 1.59-1.32 (m, 9H), 1.24 (d, J = 7.1 Hz, 3H), 1.15 (d, J = 6.3 Hz, 3H),
1.00-0.58 (m, 18H).
L1.3 Peptide Sequence: tllarl-CONH2
Confirmation by MS (MALDI-TOF): m/z 685.361; calc’d for C31H61N10O7+ 685.891. 1H
NMR (500 MHz, DMSO-d6, 308K) δ 8.53 (d, J = 8.0 Hz, 1H), 8.19 (d, J = 7.9 Hz, 1H),
8.09 (s, 3H), 7.93 (dd, J = 10.8 Hz, J = 7.3 Hz, 2H), 7.78 (d, J = 8.3 Hz, 1H), 7.54 (t, J = 5.7
Hz, 1H), 7.26 (s, 2H), 6.96 (s, 2H), 4.44-4.36 (m, 1H), 4.35-4.14 (m, 4H), 3.78 (t, J = 6.8
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Hz, 1H), 3.58 (s, 1H), 3.09 (q, J = 6.5 Hz, 3H), 1.83-1.54 (m, 5H), 1.58-1.32 (m, 9H), 1.21
(d, J = 7.1 Hz, 4H), 1.14 (d, J = 6.3 Hz, 3H), 1.01-0.64 (m, 18H).
L1.4 Peptide Sequence: AAc-tllral-COOH
Confirmation by MS (MALDI-TOF): m/z 769.475; calc’d for C33H61N12O19+ 769.467. 1H
NMR (500 MHz, DMSO-d6) δ 8.16 (d, J = 7.9 Hz, 1H), 8.11 (d, J = 8.2 Hz, 1H), 8.04 (d, J
= 8.1 Hz, 1H), 7.98-7.83 (m, 1H), 7.44 (s, 1H), 4.46-4.06 (m, 6H), 3.96 (d, J = 2.6 Hz, 3H),
3.10 (t, J = 6.8 Hz, 2H), 1.76-1.56 (m, 4H), 1.59-1.38 (m, 9H), 1.23 (d, J = 7.1 Hz, 3H), 1.06
(d, J = 6.3 Hz, 3H), 0.90-0.74 (m, 18H).
L1.5 Peptide Sequence: K(N3)LARLLT-CONH2
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Confirmation by MS (MALDI-TOF): m/z 839.421; calc’d. for C37H71N14O8+ 839.558. 1H
NMR (500 MHz, DMSO-d6 308K) δ 8.45 (d, J = 8.2 Hz, 1H), 8.17 (d, J = 7.2 Hz, 1H), 8.06
(s, 4H), 7.91 (dd, J = 14.7 Hz, J = 8.2 Hz, 3H), 7.43 (d, J = 11.0 Hz, 2H), 7.08 (d, J = 12.7
Hz, 2H), 4.88 (t, J = 5.3 Hz, 1H), 4.46-4.24 (m, 6H), 4.13-3.97 (m, 3H), 3.79 (s, 1H), 3.09
(q, J = 6.5 Hz, 2H), 1.75-1.57 (m, 6H), 1.57-1.43 (m, 11H), 1.37 (t, J = 7.5 Hz, 2H), 1.20 (d,
J = 7.1 Hz, 4H), 1.00 (d, J = 6.3 Hz, 4H), 0.93-0.80 (m, 18H).
L1.6 Peptide Sequence: GLARLLT-CONH2
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Confirmation by MS (MALDI-TOF): m/z 742.991; calc’d. for C33H64N11O8+ 742.493. 1H
NMR (500 MHz, DMSO-d6, 308K): δ 8.44 (d, J = 8.3 Hz, 1H), 8.30 (d, J = 7.2 Hz, 1H),
8.13 (d, J = 8.0 Hz, 2H), 8.01-7.86 (m, 4H), 7.43 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 13.4 Hz,
3H), 4.57-4.37 (m, 1H), 4.38-4.17 (m, 4H), 4.11-3.96 (m, 3H), 3.84 (d, J = 5.6 Hz, 1H), 3.08
(q, J = 6.5 Hz, 2H), 1.72-1.54 (m, 5H), 1.54-1.33 (m, 10H), 1.20 (d, J = 7.1 Hz, 3H), 0.99 (d,
J = 6.3 Hz, 4H), 0.97-0.72 (m, 18H).
L1.7 Peptide Sequence: KLARLLT-CONH2
Confirmation by MS (MALDI-TOF): m/z [M+H] 814.055; calc’d C37H73N12O82+ 814.547.
NMR (500 MHz, DMSO-d6, 308K) δ 8.49 (s, 1H), 8.25 (d, J = 7.3 Hz, 1H), 8.14 (d, J =
7.8 Hz, 4H), 7.97-7.87 (m, 3H), 7.52 (d, J = 5.5 Hz, 1H), 7.44 (d, J = 8.6 Hz, 2H), 7.08 (d, J
= 9.8 Hz, 2H), 4.39 (q, J = 7.1 Hz, 2H), 4.37-4.24 (m, 5H), 4.10-4.03 (m, 2H), 3.78 (s, 1H),
3.08 (d, J = 7.2 Hz, 4H), 2.75 (t, J = 7.8 Hz, 2H), 1.70-1.55 (m, 6H), 1.56-1.42 (m, 10H),
1.26-1.17 (m, 6H), 0.99 (d, J = 6.3 Hz, 4H), 0.93-0.80 (m, 18H).

1H

Synthesis of cyclic peptides Cyclo.L1 and Cyclo.L1.1
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One gram of CTC resin (16) (1.2 mmol/g) was placed in a polypropylene reaction vessel
fitted with a polypropylene frit. The resin was swollen with dry DCM (10 mL/gram of resin)
for 30 minutes after which the solvent was removed. Fmoc-Leu-OH (297 mg, 0.84 mmol,
0.7 equivalents) was dissolved in dry DCM (10 mL) and DIEA (730 uL, 3.5 equivalents)
was added. The amino acid solution was added to the resin and shaken for 1 hour. After this
time, the resin was drained and washed with DMF (6 × 3 min). Unreacted sites on the resin
were capped with DCM/MeOH/DIEA (80:15:5) twice for 15 minutes. The resin was washed
again with DMF (5 × 30 sec) followed by DCM (5 × 30 sec). After drying the resin under
vacuum overnight, the substitution level of the resin was determined by a quantitative Fmoc
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test (17). After the substitution level was determined (usually about 0.5 mmol/g), the FmocLeu-CTC resin was deprotected using 20% piperidine in DMF (2 × 5 min) and washed with
DMF (5 × 30 sec) followed by DCM (5 × 30 sec). The H-Leu-CTC resin was dried under
vacuum and then stored at 4°C. The above procedure was repeated using Fmoc-(d)Leu-OH
for peptide Cyclo.L1.1.

Author Manuscript
Author Manuscript

The Cyclo.L1 and Cyclo.L1.1 were prepared on a Tribute peptide synthesizer (Protein
Technologies, Tucson, AZ) utilizing a standard Fmoc peptide chemistry protocol on a 100
μmol scale using the previously loaded H-Leu-CTC and H-(d)Leu-CTC resins, respectively.
Side-chain functionalities were protected with tert-butyl (Thr), NG-2,2,4,6,7pentamethyldihydrobenzofuran-5-sulfonyl (Arg) and tert-butyloxycarbonyl (Lys). In the case
of peptide Cyclo.L1.1, Fmoc-Lys(N3)-OH was used. Five fold excess of Fmoc-amino acids
and HCTU, in the presence of 10 equivalents of DIEA, were used for each of the coupling
steps (10 min) with DMF as the solvent. After the synthesis of each sequence was complete,
the final Fmoc groups were removed using 20% piperidine in DMF (1 × 5 min; 1 × 10 min).
The resin from each synthesis was washed with DMF (5 × 30 sec) and DCM (5 × 30 sec).
The side chain protected peptides were cleaved from the resin with 5 mL of 1% TFA in
DCM for 5 min. The cleavage reactions were repeated 10 times. The cleavage solutions for
each respective peptide were combined and concentrated under vacuum. The residues were
dissolved in water:acetonitrile containing 0.05% TFA (1:1, 20 mL), frozen and lyophilized
to yield white solids. The peptides were dissolved in DMF to yield 2 mM solutions after
which HATU (2.5 equivalents) and DIEA (5 equivalents) were added. The cyclization
reactions were stirred for 3 hours, and then the peptides were placed under high vacuum to
remove the DMF (usually overnight) to yield an oil. Protecting groups were removed from
the peptides using TFA/water/TIPS (3 mL, 96:2:2) for 2.5 hours. Cold diethyl ether was then
added to the peptide solutions to precipitate the crude cyclized peptides. The peptides were
centrifuged for 10 minutes (10,000 rpm) and the ether layers decanted. Fresh cold diethyl
ether was added, and the pelleted peptides were re-suspended. The peptides were
centrifuged again, and the procedure was repeated 5 times for each peptide. After the final
ether wash, the peptide pellets were dissolved in a minimal amount of water containing 0.1%
TFA, frozen and lyophilized.
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HPLC analysis was performed with a Waters 616 pump, Waters 2707 Autosampler, and 996
Photodiode Assay Detector which are controlled by Waters Empower 2 software. The
separation was performed on an Agilent Zorbax 300 SB-C18 (5 um, 4.6 × 250 mm) with an
Agilent guard column Zorbax 300 SB-C18 (5 um, 4.6 × 12.5 mm). Elution was done with a
linear 5% to 55% gradient of solvent B (0.1% TFA in acetonitrile) into A (0.1% TFA in
water) over 50 min at a 1 mL/min flow rate with UV detection at 215 nm. Preparative HPLC
runs were performed with a Waters prep LC Controller, Waters Sample Injector, and 2489
UV/Visible Detector that are controlled by Waters Empower 2 software. The separation was
performed on a Agilent Zorbax 300SB-C18 PrepHT column (7 um, 21.2× 250 mm) with
Zorbax 300SB-C18 PrepHT guard column (7 um 21.2 × 10 mm) using a linear 5% to 55%
gradient of solvent B (0.1% TFA in acetonitrile) into A (0.1% TFA in water) over 50 min at
a 20 mL/min flow rate with UV detection at 215 nm. Fractions of high (>95%) HPLC purity
with the expected mass were combined and lyophilized. High resolution mass spectra were
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obtained for Cyclo.L1 and Cyclo.L1.1. All analytical data are provided in the supporting
information and Table S1.
Cyclo.L1. Peptide sequence: Cyclo(KLARLLT)—Confirmation by MS (MALDITOF): m/z 796.609; calc’d. for C37H70N11O8+ 796.540. 1H NMR (500 MHz, DMSO-d6) δ
8.51 (d, J = 8.9 Hz, 1H), 8.43 (d, J = 5.6 Hz, 1H), 8.30 (d, J = 7.4 Hz, 1H), 8.10 (s, 1H), 7.78
(t, J = 9.6 Hz, 2H), 4.32-4.27 (m, 2H), 4.24-4.20 (m, 6H), 4.03 (q, J = 7.3 Hz, 1H), 3.91-3.89
(m, 1H), 2.93 (d, J = 50.6 Hz, 6H), 2.77 (t, J = 8.4 Hz, 1H), 1.81-1.76 (m, 5H), 1.64-1.49 (m,
12H), 1.29 (d, J = 7.2 Hz, 4H), 1.09 (d, J = 6.3 Hz, 1H), 1.03 (d, J = 6.4 Hz, 4H), 0.97 (d, J =
6.6 Hz, 4H), 0.90-0.85 (m, 18H). Detailed 1H 2D NMR data with chemical shifts of protons
with assignments are provided in the Supporting Information.
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Cyclo.L1.1. Peptide sequence: Cyclo (K(N3)larllt)—Confirmation by MS (MALDITOF): m/z 822.616; calc’d. for C37H68N13O8+ 822.530. 1H NMR (500 MHz, DMSO-d6) δ
8.23 (dd, J = 21.2, 7.5 Hz, 1H), 8.07 (d, J = 37.3 Hz, 1H), 7.91 (d, J = 9.3 Hz, 2H), 7.53 (t, J
= 5.4 Hz, 1H), 4.37- 4.32 (m, 4H), 4.16 (q, J = 7.3 Hz, 2H), 4.09 (dd, J = 9.8, 5.4 Hz, 3H),
4.16-4.01 (m, 4H), 3.94 (d, J = 7.9 Hz, 1H), 1.77 (m, 7H), 1.54-1.50 (m, 6H), 1.56 – 1.50
(m, 11H), 1.35 (d, J = 7.3 Hz, 4H), 1.07 (d, J = 5.9 Hz, 4H), 0.91-0.85 (m, 18H). Detailed
1H 2D NMR data with chemical shifts of protons with assignments are provided in the
Supporting Information.
Circular dichroism spectroscopy
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Circular dichroism (CD) data was collected (Jasco J-815 spectrometer) using 1 mm path
length quartz cell. The linear and cyclic peptides were dissolved in water or methanol at a
concentration of 1 mg/mL. Spectra were acquired at room temperature with an average of
four scans in the wavelength range of 190 to 260 nm. The spectra were baseline corrected.
2D NMR of cyclic peptides
NMR studies of cyclic peptides Cyclo.L1 and Cyclo.L1.1 were carried out in 90% H2O/
10 %D2O/DSS as well as in 100% DMSO-d6. NMR data were collected using a Bruker AVIII 500 MHz spectrometer with a liquid nitrogen cooled Prodigy TCI probe. The strongest
solvent peak was suppressed by using excitation sculpting with gradients. 1D NMR
experiments were performed at temperatures in the range 25 to 37 °C and 2D NMR
experiments were performed at 25 °C. A DQF-COSY, TOCSY (80 msec mixing time),
NOESY (150 and 300 msec mixing time) and ROESY (300 msec spin-lock time) were
performed. Data were processed in SPARKY format, and analysis was done using SPARKY
software (18).
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Molecular modeling of peptides
Linear structures of the peptides were built using InsightII (BIOVIA Sandiego, CA). Linear
structures were cyclized using NMR distance restraints obtained from NOESY/ROESY
connectivities as described in our previous publications and literature (19–21). Peptide bond
was formed once the distance of the N and C-termini were within 2 Å. Cyclized peptides
were further subjected to simulated annealing procedure with NMR restraints. From hightemperature dynamics (900 K dynamics) 6 random structures were selected, and these
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structures were subjected to dynamics with NMR restraints at temperatures 800 K to 400 K
in steps of 100 K with each step 10 ps duration. Structures from 400 K dynamics were used
to soak 8 Å layer of water molecules and subjected to MD simulations for 20 ps. From this
300 K dynamics, 5–7 structures were chosen and subjected to energy minimization, first
with steepest descent methods and then conjugate gradient method for 4000 steps with rms
derivative of 0.5 kcal/mol-Å2. A total of 70 structures were generated. These structures were
verified for NMR distance restraints, and structures that satisfied all the NMR distance
restraints were considered as a probable structure of the peptide in solution. These structures
were overlapped and represented using PyMol software.
Docking
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Autodock Tools and Autodock (22) version 4.2 software was used for docking studies.
Three-dimensional structures of EGFR in the open (3njp) (23) and closed (1nql) (24)
conformations were obtained from the protein data bank. A three-dimensional structure of
peptides was generated using InsightII (BIOVIA, San Diego, CA) as described above.
Solvent molecules were removed from the protein file. Using the previously published
procedure, the binding site of peptides on EGFR was assumed to be around Glu71, Asn134,
and Gly177. A grid was created around the binding site with 126×126×126 Å3 box. Threedimensional structures of peptides were used for docking studies with the Lamarckian
genetic algorithm as described in our earlier studies (6). Briefly, 150 starting conformations
with 10 million energy evaluations were done, and final 50 low-energy docked structures
were analyzed. Final lowest energy docked structure was used for presentation using PyMol
software (Schrodinger LLC, Portland, OR). Docking studies were carried out on a highperformance computer (HPC) at LSU, Baton Rouge via the Louisiana Optical Network
Initiative (LONI).

Author Manuscript

Antiproliferative activity
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Colon cancer cell line SW480 (ATCC® Number: CCL-228™) were purchased from ATCC.
Cells were grown to confluency using the Leibovitz’s L-15 Medium. Antiproliferative
activity was measured by CellTiter-Glo®, (25) cell viability assay. Nearly 1 × 104cells/well
were seeded and incubated overnight at 37 °C and 5% CO2. Peptide solutions were prepared
by dissolving 1.5 mg/mL of the peptide in deionized water and diluted using serum-free
medium to prepare solutions of different concentrations of the peptide. For each
concentration triplicate experiments were performed by incubating the peptide with cells for
72 h. Cells treated with 1% sodium dodecyl sulfate, and medium without the compound
were used as controls. At the end of the experiment, CellTiter-Glo® reagent was added, and
luminescence was measured using a plate reader. IC50 values were obtained from doseresponse curves (GraphPad software, La Jolla, CA). Experiments were repeated at least three
times to obtain standard deviation values.
SPR
Surface Plasmon Resonance was performed at 25°C using Biacore ×100 (GE Healthcare
Biosciences, Piscataway, NJ), as described in detail in our previous publication (26). Briefly,
the pure recombinant extracellular domain of EGFR protein (Leinco Technologies, St.
Louis, MO) was immobilized on the CM5 SPR sensor chip (GE Healthcare Biosciences) at a
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rate of 5 μL/min in sodium acetate buffer (pH 4.5) using a standard amine coupling
procedure. Before binding studies were performed, different concentrations of EGFR protein
(0.1 to 1 μM) at different pH values including pH 4.0, 4.5, 5.0 and 5.0 (acetate buffers) were
used for immobilization of the protein. We have selected the optimum concentration and pH
value to obtain about 4000 to 5000 relative response units for protein immobilization and
this was used as baseline with protein. Different peptides with concentrations ranging from 0
to 200 μM were used as analytes with HBS-EP (GE Healthcare Lifesciences, PA) as running
buffer at a flow rate of 30 μL/min. The KD value was determined by fitting the obtained
sensorgrams in Langmuir’s equation for 1:1 binding by using Biacore evaluation software.
Curve fitting was analyzed by evaluating the chi squared value.
Stability of peptides in serum

Author Manuscript

Human serum (Innovative Research Novi, MI) was used according to approved guidelines,
in a biosafety II cabinet with IBC certification. The detailed method for stability of peptides
in serum was described in our previous publication (26). Peptide solutions were prepared in
PBS at a concentration of 2 mg/mL, added to human serum in the ratio of 1: 9 and incubated
at 37 °C. At different time points (0 min to 48 h), an aliquot of 100 μL was taken out and
treated with 500 μL of cold acetonitrile for peptide extraction. Samples were analyzed by
RP-HPLC as described previously (26). Relative intensity (AUC) for each time point,
considering zero time point as 100% peptide concentration was plotted with respect to time,
from triplicate experiments. The freeze-dried samples obtained from HPLC analysis were
further analyzed by MALDI-TOF-MS using α-cyano-4hydroxy-cinnamic acid as the matrix
gel.

Results
Author Manuscript

Peptide Design
Based on our previous studies using L1, we designed and synthesized the peptide derivatives
shown in Table 1, with the aim to enhance the stability of L1. In the cyclic peptides with
backbone cyclization, a lysine residue was introduced at the N–terminus for subsequent
conjugation with a fluorophore. Similarly, for the linear peptide derivatives, a glycine or
lysine residue was introduced to facilitate fluorophore conjugation. In addition, to improve
peptide stability, several derivatives were synthesized with D-amino acids, with or without
reversal of sequence, and N-termini stabilizing acetyl groups (Table 1).

Author Manuscript

The linear peptides likely exhibit unordered or flexible structure in solution. However, in the
presence of EGFR, L1 might acquire a folded stable structure that maximizes interactions
with the protein. To verify this, we performed docking studies of peptide L1 with EGFR.
Several low energy docked structures of L1 were analyzed for the possible folded structures
of the peptide. Figure 1 indicates that the L1 peptide acquires a folded structure in the
presence of the protein. Careful observation of these docked structures suggests that there is
a possibility of a turn structure in the peptide in the bound state. Based on this observation,
and to increase the peptide stability, we investigated cyclization of the L1 peptide. However,
the direct cyclization of L1 would result in a cyclic structure without the N or C-termini, and
without functionality for subsequent conjugation to a fluorophore, such as a free amino
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group. Hence a lysine residue was introduced in the peptide sequence at the N-terminus. The
side chain of Lys can be used for subsequent conjugation to a fluorophore via amide bond
formation. In addition, we introduced an azide group at the lysine side chain to allow
conjugation via “click” chemistry. To further increase the peptide stability and to facilitate
the cyclization reaction, we also used D-amino acids with the exception of Lys-azide, in the
preparation of peptide Cyclo.L1.1. (Figure 2 A&B)
Circular Dichroism (CD) Studies

Author Manuscript

To evaluate the changes in the overall conformation of the linear, cyclic and D-amino acids
peptides, CD studies were conducted. The CD spectra of L1.7 and Cyclo.L1 peptides
exhibited a negative band around 198 nm in water suggesting flexible backbone
conformations for these peptides in water (27). Peptide Cyclo.L1.1 exhibited a positive band
around 198 nm indicating a change in chirality of L to D amino acids in the peptide (Figure
3A). In methanol, the negative and positive bands of the peptides around 198 in water shifted
to 200 nm. Furthermore, an additional CD band around 220 nm appeared, suggesting the
possibility of a well-defined β-turn conformation of the peptides in an organic solvent (27)
(Figure 3B). CD spectra of linear and cyclic peptides studied are provided in the supporting
information.
SPR Studies
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Among the peptides studied, L1, L1.3, L1.5, L1.6, L1.7, Cyclo.L1 and Cyclo.L1.1 (Table
1) exhibited binding to the EGFR protein in a concentration-dependent manner (Figures 4
and 5 and SI). Peptides L1.1, L1.2, and L1.4 did not show any binding to EGFR as seen by
SPR. As expected and as previously reported (8, 9), the L1 peptide showed an affinity for
binding to EGFR. Cyclic peptide Cyclo.L1 and the Cyclic peptide with azide side chain and
D-amino acids Cyclo.L1.1 exhibited binding to EGFR (Figures 4 and 5).

Author Manuscript

The kinetics of binding of cyclic peptides to EGFR were analyzed assuming Langmuir 1:1
binding and the sensorgrams were fit using the Langmuir equation to provide the KD values.
The Cyclo.L1 and Cyclo.L1.1 peptides were found to have KD values of 1 and 5 μM,
respectively, while the linear peptide L1 exhibited a KD value of 8 μM, indicating relatively
higher binding affinity of the cyclic peptides to EGFR. It should be noted that the
immobilized EGFR did not have EGF bound to it and hence we assume that the EGFR was
mainly in a closed conformation. Peptide L1 is known to bind to EGFR in both the open and
closed EGFR conformations. In order to evaluate the specificity of Cyclo.L1.1 binding to
EGFR, SPR analysis was also carried out using the homologous proteins HER2 and HER3
(28). The analysis indicated that Cyclo.L1.1 binds to HER2 with a KD value of 40 μM, and
to HER3 with a KD value of 50 μM.
NMR Studies
To investigate the 3D structures of Cyclo.L1 and Cyclo.L1.1, the 1D and 2D NMR spectra
of these cyclic peptides were obtained, both in water and in DMSO-d6. The amide
resonances of both the peptides were dispersed around 1 ppm, suggesting well-defined
conformations for the peptides in solution. All the amino acid resonances could be identified
using DQF-COSY and TOCSY spectra. Sequence-specific assignments were performed
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using NOESY and ROESY spectra (29) (Figure 6). Both peptides have three leucine amino
acids, and the amide resonances of two leucine amino acids were merged, indicating similar
chemical environment for those amides in solution. The NMR spectra of the peptides in
water exhibited limited spatial connectivities in ROESY and NOESY spectra, and hence
detailed 2D NMR studies were carried out in DMSO-d6. Both cyclic peptides have similar
amino acids in the sequence, however, Cyclo.L1.1 has all D-amino acids except for lysine,
and the L-Lys has an azide group at the side chain. Most of the amino acids exhibited similar
chemical shifts for the amide resonances in both peptides, except for K1 and A3. The
chemical shift, temperature dependence of amide resonances, and coupling constants of
amide resonances are provided in the Supporting Information. For Cyclo.L1, the
temperature dependence of the chemical shift for the amide resonances of L2, R4, L5, and
L6 was ≤ 4.3 ppb/K, indicating that the amide protons of these amino acid residues were
solvent shielded or involved in intramolecular hydrogen bonding (30). In the case of
Cyclo.L1.1, the l2, l6 and t7 amide protons appear to be intramolecularly hydrogen bonded
or solvent shielded. For Cyclo.L1, the 3JHNα coupling constants of L2 to L6 were ≤ 5Hz,
whereas T7 has a coupling constant > 8 Hz suggesting that the peptide has a well-defined
turn structure. In the case of Cyclo.L1.1, the 3JHNα coupling constants of l2, a3 and t7 were
≤ 5Hz and for K1, r4, l5 and l6 the coupling constant values were > 8 Hz, suggesting an
extended structure of the peptide. In NOESY spectra, the peptide Cyclo.L1 exhibited spatial
connectivity between the NH of R4-L5, the NH of T7-K1. Other spatial connectivities were
sequential and within the same residue (Figure 6A&B). In the case of Cyclo.L1.1, spatial
connectivity was observed between the NH of t7-l6,5, the NH of l2-K1 and other spatial
connectivities were sequential or within the same amino acid residues (Figure 6C&D).
Molecular Modeling
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Based on the NMR-derived NOESY/ROESY distance restraints, possible 3D structures of
peptides Cyclo.L1 and Cyclo.L1.1 were proposed and investigated. For Cyclo.L1, 43 NMRbased distance restraints were obtained, and for Cyclo.L1.1 40 distance restraints were
obtained. Based on these restraints, the structures of these peptides were elucidated using
distance-restrained MD simulations and energy minimization calculations. The structure of
the Cyclo.L1 peptide exhibits two β–turns stabilized by intramolecular hydrogen bonding
(Figure 7A). The first β-turn (31) occurs at T7-K1-L2-A3 with Φ, Ψ values of −40, −50 and
−73, −12 at K1 and L2, respectively. This turn is stabilized by hydrogen bonding between
the C=O of T7 and the NH of A3. The second β-turn is at R4-L5-L6 and T7 with Φ, Ψ
values of −69, −94, −87, −4 at L5 and L6, respectively. The second turn is also stabilized by
intramolecular hydrogen bonding between C=O of R4 and the NH of T7. There is one
additional hydrogen bond between C=O of T7 and the NH of R4. The participation of amide
protons in intramolecular hydrogen bonding between the C=O of R4 with the NH of T7, and
the C=O of T7 with the NH of R4, is supported by the low-temperature coefficient chemical
shift of R4 and T7 amides (Supporting Information). Overall, the structure of the peptide
features a stable backbone conformation, and the 25 overlapped structures of Cyclo.L1 show
that the average rms deviation of the backbone structure is 1.25 ± 0.36 Å (Figure 7C). The
side chains of L2, A3, L5, L6 and T7 are oriented on one face of the peptide backbone
plane, and R4 is on the opposite side of this peptide backbone plane. The K1 side chain is
folded in the plane of the peptide backbone.
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The structure of peptide Cyclo.L1.1 is slightly different from that of Cyclo.L1. The
backbone structure of Cyclo.L1.1 (Figure 7B) does not exhibit well-defined β-turns, as in
the case of Cyclo.L1. The first β-turn is at l2-a3-r4-l5 with Φ, Ψ values of −46, 126, 70, 23
at a3 and r4, respectively. The hydrogen bond is between C=O of l2 and the NH of l5. The
second β-turn is at l5-l6-t7-K1 with Φ, Ψ values of 140, −58, −44, 111. This turn is not
stabilized by hydrogen bonding as the NH of K1 moved away from the C=O of l5. There is a
γ-turn type of hydrogen bond between the C=O of l5 and the NH of t7. The hydrogen
bonding between the C=O of l5 and the NH of t7 is supported by the low-temperature
coefficient of the amide proton of t7. Unlike the Cyclo.L1 peptide conformation, the turn
structure in Cyclo.L1.1 is not stabilized by hydrogen bonds. This is also supported by the
high-temperature coefficient of the chemical shifts of K1, a3, r4, and l5. Most of the side
chains face one side of the peptide backbone plane, except for the K1 side chain. This may
be because K1 is an L-amino acid residue while the remaining amino acids in the peptide
have D-chirality. The average rms deviation of the backbone of 25 overlapped structures is
1.60 ± 0.54 Å (Figure 7D).
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To model the binding of these peptides to EGFR, docking studies were carried out using
Autodock (22). The linear peptide L1 is known to bind to the domain I of the EGFR protein,
away from the EGR binding pocket (32, 33). Cyclo.L1 was docked near the presumed L1
binding site, as reported in our previous studies (6). The low energy docked structure of
Cyclo.L1 is shown in Figure 8A. The lowest energy docked structure (−2 kcal/mol) forms
six hydrogen bond interactions with the EGFR protein, stabilizing the ligand-receptor
interactions. The hydrogen bonds are between the NH of L6 and the C=O of Gln184, the
C=O of L6 and the NH of Leu186, the C=O of R4 and the Lys185 side chain amine group,
the NH of L2 and the C=O of Arg200, the side chain of T7 and the C=O of Leu186, and
between the side chain of R4 and the C=O of Glu180. The peptide-EGFR interaction is also
stabilized by hydrophobic interactions between the L6 side chain and Pro171 and Leu186, as
well as between the L5 side chain and Arg4, Cys170, and Cys183. The lowest energy
docked structure of Cyclo.L1.1 was on EGFR domain I (Figure 8B). In terms of docking
energy, both peptides were within the error of docking energy (2 kcal/mol) (22). The
docking site on domain I of EGFR is the same as the site occupied by the Cyclo.L1 peptide.
However, Cyclo.L1.1 is stabilized by two hydrogen bond interactions, at t7 side chain with
the C=O of Leu186, and the K1 side chain with Gln184. The hydrophobic interactions were
between the l2 side chain and Leu186, Ile189, Ile190 and the K1 side chain with Glu181
side chain, l5 side chains with Arg200 side chain and the Thr217 methyl groups (Figure 8B).
Antiproliferative activity
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To evaluate whether the designed peptides cause any antiproliferative activity, peptide
Cyclo.L1.1 was selected to be evaluated for its ability to inhibit growth in EGFR
overexpressing SW480 cells. From the dose response curve, the IC50 value was found to be
>100 μM suggesting that this peptide does not cause any growth inhibition and hence it is
not toxic to EGFR overexpressing cells.
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The stability in human serum of the linear and cyclic peptides KLARLLT (L1.7) and
cyclo(KLARLLT) (Cyclo.L1) were compared, and the results obtained are shown in Figure
9. In these studies, the peptides were incubated in human serum at 37 °C, and samples were
analyzed using HPLC at different time points up to 48 h. The area under the curve (AUC) at
each time point of the peptide peak was plotted vs time to assess the stability, assuming the
AUC at 0 h as 100%. The linear peptide L1.7 exhibited a sharp decay curve (Figure 9A)
indicating fast degradation of this peptide, with only 10% intact after 48 h and a half-life of
about 5 h. On the other hand, the cyclic peptide Cyclo.L1 exhibited slower degradation, with
nearly 60% of the peptide intact after 48 h (Figure 9B). The degradation profile for
Cyclo.L1 was constant after 6 h, suggesting that there is a possibility of peptide binding to
serum proteins (34), however, further studies are needed to differentiate the amount of
degradation of cyclic peptide and serum bound peptide. The samples were also analyzed
using mass spectrometry to confirm the presence of intact peptide at the various time points.
The molecular ion (m/z) corresponding to the peptide molecular weight was observed for all
the samples collected at the different time points, indicating the presence of intact peptide at
all time points, in agreement with the HPLC results.

Discussion
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The main goal of our studies was to design peptide derivatives of L1 with enhanced stability
and binding affinity to EGFR domain I. Peptides that are specific for extracellular receptors
can be used for targeting drugs to those receptors and/or for conjugation with fluorescent
probes for molecular imaging. In the present work we designed and investigated derivatives
of the linear peptide L1, known to bind to the EGFR extracellular domain I. The designed
peptides (Table 1) were modified at the N-terminus, or with an azide-containing Lys side
chain, to facilitate their subsequent conjugation to fluorescent probes, such as 4,4difluoro-4-bora-3a,4a-diaza-s-indacenes (BODIPYs), using either amide bond formation or
click chemistry. Our previous studies showed that peptide L1 conjugated to a phthalocyanine
or porphyrin increases the uptake of the fluorophore by up to 17-fold in cells overexpressing EGFR (6). However, one main disadvantage of peptides is their susceptibility to
degradation in vivo (11, 12). Peptides can be designed with improved stability by
modification of their structure, for example by cyclization via a disulfide bond or main chain
cyclization, and by substitution with D-amino acids at crucial positions (13). In addition,
conformational constraints, such as a β-turn (35), can be used for optimization of the
binding activity of peptide ligands. Changing the chirality of the amino acids in L1 and/or
reversing the sequence as in L1.1 and L1.2 (Table 1), do not favor the binding of the peptide
to EGFR. Furthermore, changing the chirality, reversing the sequence, and capping the Nterminus of the peptide (L1.4) also do not favor EGFR-binding. However, changing the
chirality of amino acids, reversing the sequence, and introducing C-terminal amidation,
resulted in retaining of the binding activity, as seen in L1.3. The addition of amino acids
such as Gly or Lys at the N-terminal of the L1 peptide, and modification of the terminal Lys
residue with azide, as in L1.5–L1.7, did not change the binding affinity of the peptide to
EGFR. Therefore, Gly or Lys amino acid spacers can be introduced to facilitate fluorescence
labeling of peptide L1 without affecting its binding affinity to EGFR. A cyclic peptide
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Cyclo.L1 with Lys in the sequence showed binding to the EGFR extracellular domain. An
analog of cyclic peptide Cyclo.L1.1 with D-amino acids and an azide group in the Lys side
chain, was also shown to bind to EGFR. The peptide L1 is known to target EGFR in vitro
and in vivo in a mouse model (9) and it does not cause any antiproliferative activity or
toxicity. To evaluate whether the cyclization of this peptide induces cytotoxicity, the
antiproliferative activity of Cyclo.L1.1 was evaluated in the colon cancer cell line SW480
known to overexpress EGFR (36). The IC50 value determined for Cyclo.L1.1 was >100 μM
indicating that this cyclic peptide does not modulate EGFR signaling processes, and does
not cause cytotoxicity.
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As mentioned above, the main goal of our studies was to design peptides that exhibit high
EGFR binding activity, and good stability in serum for in vivo studies. Cyclo.L1 was
evaluated for its serum stability using human serum in vitro, and its stability was compared
to its linear analog L1 using HPLC and MS techniques. These stability studies clearly
suggested that Cyclo.L1 is more stable compared with linear peptide L1 in serum. From the
stability profile of Cyclo.L1 it is clear that within the first 2 h nearly 40% of the intact
peptide was lost. Possible reasons for the loss of 40% of peptide could be the existence of a
racemic mixture and loss of one form of the peptide, and the binding of the peptide to serum
proteins. Considering the synthesis procedure and the CD spectra that clearly represent the
relative chirality of the peptide (Figure 3 and Supporting Information), we hypothesize that
binding of the peptide to serum proteins is the most likely cause of nearly 40% loss of the
peptide observed in the stability studies. We rule out the proteolysis process as the intact
peptide amount was constant after 4 h and up to 48 h. To differentiate between serum protein
binding and proteolysis, future studies will investigate serum protein binding by both SPR
and dialysis.
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The design of cyclic peptides was based on conformational studies of the parent linear
peptide in bound form with EGFR using docking models. Linear peptides with flexible
structure may change their conformation upon binding to the receptor and therefore may
exhibit different conformation in the free state compared with the bound state. On the other
hand, cyclic peptides with constrained structure may not change their conformation
significantly upon binding to the receptor as their conformation is restricted (37). Hence, the
design of cyclic peptides is important in terms of binding to the receptor. Upon cyclization,
if the conformation is not suitable for binding, the binding affinity of the cyclic peptide to
the receptor decreases significantly compared with the linear peptide. The structure of the
peptides derived from NMR and modeling studies indicated that peptide Cyclo.L1 exhibited
two β-turns and these β-turns were stabilized by hydrogen bonds. Cyclo.L1.1 exhibited βturns, however, NMR and molecular modeling studies suggested that the β-turn was not
stabilized by hydrogen bonds. Thus, in solution, the backbone conformation of Cyclo.L1.1
was different from that of Cyclo.L1. We believe that introduction of D-amino acids in the
peptide, with exception of Lys, lead to this change in conformation. The conformations of
cyclic hexapeptides have been studied extensively. Usually, cyclic hexapeptides acquire
well-defined backbone structures and cyclic hexapeptides containing trans-amide bonds
exhibit two β-turns stabilized by intramolecular hydrogen bonds (38). The occurrence of
intramolecular hydrogen bonds in cyclic peptides also depends on the overall backbone
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conformation of the peptide. Nielsen et al. (39) studied cyclic hexapeptides with different
number of proline residues in the peptide sequence. Their study suggested that cyclic
hexapeptides without a proline have relatively flexible backbone conformations in solution
compared with cyclic peptide with prolines. Cyclic peptides with anticancer properties and
orally available have been reported. The stability and increase in anticancer activity of a nine
amino acid residue peptide compared to the linear peptide were attributed to its
conformational constraints (40–42). Compared with the linear peptide L1, Cyclo.L1 and
Cyclo.L1.1 acquire restricted conformations that are suitable for binding to the EGFR
receptor. This conformational locking is achieved by cyclization of the linear peptide. To
compare the conformation of linear peptide in bound form to the structure of cyclic peptides
derived from NMR data, we overlapped the NMR-derived structure of Cyclo.L1 and its
docked structure, with those obtained for the linear peptide L1. Figure 10A compares the
structures of the L1 linear peptide in the EGFR-docked conformation with the NMR-derived
structure of Cyclo.L1. One can see that the backbone of RLLT overlaps with the cyclic
peptides. Similarly, the final docked structure of Cyclo.L1 overlaps with the linear LARLLT
docked structure, showing a good overlap of the peptide backbones (Figure 10B). The
overlapped structure suggests that the linear and cyclic peptides fold in a similar
conformation in the presence of EGFR in the bound form. Therefore, the cyclization of
peptide L1 results in a conformation that is ready to bind to the EGFR protein. Docking
results suggest that Cyclo.L1 and Cyclo.L1.1 bind to the domain I of EGFR and this site is
away from the EGF binding site. Furthermore, cyclic peptides bind to both the open and
close conformations of EGFR (28), since the docking site on domain I is not affected by
these conformational changes in EGFR. The model proposed based on docking studies is
also supported by SPR studies that indicate that Cyclo.L1 and Cyclo.L1.1 bind to EGFR in
the absence of EGF ligand, indicating that the conjugates also bind to EGFR in a closed
conformation. Previous studies on affibody molecules designed to bind to EGFR have
suggested that molecules that are designed to bind to domain I may bind to the open or
closed conformations of EGFR (43). Overall, these results suggest that both cyclic peptides
based on linear L1, Cyclo.L1, and Cyclo.L1.1, specifically bind to EGFR, and therefore
could be used in the design of fluorescent EGFR-targeting conjugates.

Conclusions
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Structure-activity studies of linear and cyclic versions of the L1 peptide, known to
specifically bind to EGFR, were conducted using CD, SPR, NMR, molecular dynamics, and
Autodock. Additional amino acid residues (Gly, Lys) were added to the linear peptide
sequence, and the effects of change of amino acid chirality and reversal of sequence were
also investigated. The L1 peptide was cyclized to improve its stability and affinity for the
EGFR protein, and a Lys residue with or without azide modification, and reversed sequence
were introduced for subsequent conjugation to a fluorophore. The cyclized peptides
exhibited higher affinity for the EGFR protein compared with the linear peptides, as
indicated by SPR analysis. Detailed CD, NMR, and molecular modeling studies suggested
that the peptides acquire a β-turn structure in solution. A model was proposed for the cyclic
peptide-EGFR interaction using a docking method. The cyclic peptides appear to bind to the
domain I of EGFR, away from the EGF binding pocket. Stability studies in human serum
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using HPLC and mass spectrometry indicated that the cyclic peptides are more stable than
the linear peptides. Our studies suggest that the cyclic peptides are efficient ligands for
EGFR, and their conjugation to a fluorescent tag could lead to an efficient strategy for the
detection of CRC and other cancers that have high EGFR expression.
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Refer to Web version on PubMed Central for supplementary material.
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ACN

Acetonitrile

BODIPY

4,4-difluoro-4-bora-3a,4a-diaza-s-indacenes

CD

circular dichroism

CTC

chlorotrityl chloride resin

DCM

dichloromethane

DIEA

diisopropylethylamine

DMF

dimethylformamide

EDTA

ethylenediaminetetraacetic acid

EDC

N-ethyl N-(dimethylaminopropyl)

EGFR

epidermal growth factor receptor

Fmoc

fluoroenylmethyloxycarbonyl

HATU

N-[(Dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridine-1-ylmethylene]-Nmethylmethanaminium hexafluorophosphate N-oxide

HCTU

2-(6- Chloro- 1H–benzotriazole-1-yl)-1,1,3,3- tetramethylaminium
hexafluorophosphate

HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HOBt

Hydroxybenzotriazole

HPC

high performace computer

HPLC

high performance liquid chromatography

MALDI-TOFmatrix-assisted laser desorption/ionization-time of flight
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MD

molecular dynamics

MeOH

methanol

MS

mass spectrometry

NHS

N-hydroxysuccinimide

NMR

nuclear magnetic resonance

PBS

phosphate buffered saline

SPPS

solid phase peptide synthesis

SPR

Surface Plasmon Resonance

TBTU

O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate

TFA

trifluoroacetic acid

TIPS

triisopropylsilane

UV

ultra violet
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Fig. 1.

Possible conformations acquired by the linear peptide L1-LARLLT in its binding pocket on
EGFR. Structures shown in B) and C) are folded in such a way that N and C-termini are
closer to form cyclic structure. Structure A) and D) show folding of backbone around A2
and R3 but the N-and C-are not in close contact. Structures D, E and F have extended
backbone structures for the amino acids R3 to T6.
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Design concept for peptides. A) Linear peptides with modification in chirality of amino
acids, N and C-termini protection and reversal of sequence. B) Design of cyclic peptide for
stability and conjugation.
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Fig. 3.

CD spectra of linear and cyclic peptides in A) water and B) methanol. CD bands around 200
and 215 nm indicate possible secondary structure of the peptides in methanol solution.
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Fig. 4.

SPR analysis of linear peptides. EGFR was immobilized on a CM5 sensor chip and different
concentrations of the following linear peptides were injected to obtain the SPR response: A)
L1), B) D amino acid sequence, L1.1), C) sequence with lysine residue, L1.7, and D)
sequence with lysine azide, L1.5.
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Fig. 5.

SPR analysis of cyclic peptides. EGFR was immobilized on CM5 sensor chip and different
concentrations of the cyclic peptides were injected to obtain the SPR response. A)
Cyclo.L1), B) Cyclo.L1.1.

Author Manuscript
Chem Biol Drug Des. Author manuscript; available in PMC 2019 February 01.

Williams et al.

Page 26

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
Chem Biol Drug Des. Author manuscript; available in PMC 2019 February 01.

Williams et al.

Page 27

Author Manuscript
Author Manuscript
Author Manuscript
Fig. 6.

Author Manuscript

2D 1H NMR data for cyclo.L1 and Cyclo.L1.1 showing folded structure of the peptide. A)
Finger print region (NH-CαH) of NOESY of Cyclo.L1. B) NH-NH region of Cyclo.L1. C)
Finger print region (NH-CαH) of NOESY of Cyclo.L1.1. D) NH-NH region of Cyclo.L1.1.
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Fig. 7.

Proposed structure of peptides A) Cyclo.L1 and B) Cyclo.L1.1 in solution based on NMR
data. Backbone structures of 25 superimposed C) Cyclo.L1 and D) Cyclo.L1.1. The L
amino acids are shown in capital letters and D amino acids are shown in small letters.
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Fig. 8.

Proposed model of A) Cyclo.L1 and B) Cyclo.L1.1 binding to EGFR based on docking
studies.
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Fig. 9.

Serum stability of A) linear peptide L1 and B) cyclic peptide Cyclo.L1 by HPLC. Data is
plotted from three experiments and error bars indicate ±SD.
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Fig. 10.

Comparison of the EGFR-docked structures of linear peptide L1 and the NMR derived and
docked cyclic peptide structures. A) Overlapped of two L1 structures docked to EGFR (red
and blue sticks) with the NMR-based structure of Cyclo.L1 (cyan sticks); B) Overlapped of
two L1 structures docked to EGFR (green and red sticks) with the low energy docked
structure of Cyclo.L1 (cyan sticks).
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Scheme 1.

General synthesis scheme for linear and cyclic peptides.
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Table 1

Author Manuscript

Peptides designed and synthesized in this studya

Author Manuscript

a

Code

Peptide sequence

Comment

bK value for EGFR
D
binding from SPR (mM)

L1

LARLLT-CONH2

Original sequence from Phage display*

8.7

Cyclo.L1

Cyclo(KLARLLT)

Cyclic version of L1 with lysine

1.16

Cyclo.L1.1

Cyclo(K(N3)larllt)

L1 cyclic D-amino acids and lysine with azide for conjugation

5.09

L1.1

larllt-COOH

Linear all D-amino acids

N.D

L1.2

tllral-COOH

Linear all D-amino acids reverse sequence

N.D

L1.3

tllral-CONH2

Linear all D-amino acids reverse sequence

N.D

L1.4

AAc-tllral-COOH

Linear reverse sequence with D-amino acids, N-terminal azidoacetate.

N.D

L1.5

K(N3)LARLLT-CONH2

L1- peptide with azide

4.21

L1.6

GLARLLT-CONH2

L1-peptide with glycine

N.D

L1.7

KLARLLT-CONH2

L1-peptide with lysine

1.25

Capital letters are used to represent L amino acids and small letters are used to represent D amino acids.

*

Song et al. FASEB J. (2009).

b

KD values were not determined for all the peptides accurately as Chi squared value was high for curve fitting.

Author Manuscript
Author Manuscript
Chem Biol Drug Des. Author manuscript; available in PMC 2019 February 01.

